China's NMPA approves Enlida (batoclimab) for generalised myasthenia gravis

China's National Medical Products Administration approved Enlida (batoclimab injection) for marketing to treat generalised myasthenia gravis, according to a PR Newswire release.

Detected & updated continuously · Source: Nebula

Story subjects

National Medical Products AdministrationEnlida (Batoclimab injection)

Track sentiment and mindshare across stocks and crypto in Nebula.

Open Nebula